Cetera Advisor Networks LLC Intellia Therapeutics, Inc. Transaction History

Cetera Advisor Networks LLC

  • $0
  • Q1 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024
BUY
$23.82 - $32.8 $782,772 - $1.08 Million
32,862 Added 383.68%
41,427 $1.14 Million
Q4 2023

Feb 13, 2024
BUY
$23.16 - $32.34 $16,235 - $22,670
701 Added 8.91%
8,565 $261,000
Q3 2023

Nov 14, 2023
SELL
$31.62 - $45.78 $150,447 - $217,821
-4,758 Reduced 37.7%
7,864 $248,000
Q2 2023

Aug 09, 2023
BUY
$34.58 - $46.03 $145,789 - $194,062
4,216 Added 50.15%
12,622 $514,000
Q1 2023

May 15, 2023
BUY
$33.3 - $44.82 $279,919 - $376,756
8,406 New
8,406 $313,000

Others Institutions Holding NTLA

# of Institutions
317
Shares Held
91.5M
Call Options Held
442K
Put Options Held
880K
View Full List

About Intellia Therapeutics, Inc.

NTLA Quotes by TradingView
  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $835M
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Cetera Advisor Networks LLC Portfolio

Follow Cetera Advisor Networks LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cetera Advisor Networks LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cetera Advisor Networks LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email